$INTI
Inhibitor Therapeutics, Inc.

2019 Q2 Form 10-Q Financial Statement

#000119312519142366 Filed on May 09, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $331.9K $594.8K $500.0K
YoY Change -7.81% 18.97% -74.87%
% of Gross Profit
Research & Development $303.6K $196.8K $674.0K
YoY Change -42.6% -70.8% -17.64%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $635.5K $791.6K $1.175M
YoY Change -28.14% -32.62% -58.24%
Operating Profit -$635.5K -$791.6K -$1.175M
YoY Change -28.14% -32.62% -58.24%
Interest Expense $2.810K $5.310K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$632.7K -$786.3K -$1.170M
YoY Change -28.1% -32.8% -58.21%
Income Tax
% Of Pretax Income
Net Earnings -$632.7K -$786.3K -$1.171M
YoY Change -28.26% -32.83% -58.21%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.708K -$2.123K $0.00
COMMON SHARES
Basic Shares Outstanding 370.4M 370.4M 369.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.025M $1.131M $1.570M
YoY Change 153.15% -27.98% -32.91%
Cash & Equivalents $2.025M $1.131M $1.573M
Short-Term Investments
Other Short-Term Assets $38.01K $46.15K $300.0K
YoY Change -86.89% -84.62% 0.0%
Inventory
Prepaid Expenses $38.01K $46.15K $51.36K
Receivables
Other Receivables
Total Short-Term Assets $2.063M $1.177M $1.875M
YoY Change 89.84% -37.22% -29.01%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $68.35K $75.67K $105.0K
YoY Change -30.0% -27.91% -21.82%
Total Long-Term Assets $68.35K $75.67K $105.0K
YoY Change -30.0% -27.91% -21.82%
TOTAL ASSETS
Total Short-Term Assets $2.063M $1.177M $1.875M
Total Long-Term Assets $68.35K $75.67K $105.0K
Total Assets $2.132M $1.253M $1.980M
YoY Change 79.96% -36.73% -28.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $195.3K $245.2K $370.1K
YoY Change -40.11% -33.76% 8.95%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $304.8K $324.8K $441.2K
YoY Change -34.02% -26.37% 11.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.000M $1.500M
YoY Change
Total Long-Term Liabilities $3.000M $1.500M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $304.8K $324.8K $441.2K
Total Long-Term Liabilities $3.000M $1.500M $0.00
Total Liabilities $3.305M $1.825M $441.2K
YoY Change 615.49% 313.64% 11.46%
SHAREHOLDERS EQUITY
Retained Earnings -$54.50M -$53.82M -$49.47M
YoY Change 8.17% 8.78% 7.61%
Common Stock $49.36M $49.28M $51.01M
YoY Change 1.27% -3.38% 5.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.173M -$572.3K -$822.4K
YoY Change
Total Liabilities & Shareholders Equity $2.132M $1.253M $1.980M
YoY Change 79.96% -36.73% -28.67%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$632.7K -$786.3K -$1.171M
YoY Change -28.26% -32.83% -58.21%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$605.5K -$978.0K -$1.132M
YoY Change -23.35% -13.58% 30.08%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.500M 1.000M 2.361M
YoY Change 14900.0% -57.64% -164.15%
NET CHANGE
Cash From Operating Activities -605.5K -978.0K -1.132M
Cash From Investing Activities
Cash From Financing Activities 1.500M 1.000M 2.361M
Net Change In Cash 894.5K 22.01K 1.229M
YoY Change -214.68% -98.21% -127.01%
FREE CASH FLOW
Cash From Operating Activities -$605.5K -$978.0K -$1.132M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369615009
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
131031
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-786288
CY2019Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
49315
CY2019Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1500000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-791600
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
791600
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
75669
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82992
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1130724
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1108713
CY2019Q1 us-gaap Assets
Assets
1252545
CY2018Q4 us-gaap Assets
Assets
1233001
CY2019Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
46152
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41296
CY2019Q1 us-gaap Assets Current
AssetsCurrent
1176876
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1150009
CY2019Q1 us-gaap Liabilities
Liabilities
1824820
CY2018Q4 us-gaap Liabilities
Liabilities
1200650
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
245152
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
384829
CY2019Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
30353
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
215876
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
324820
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
700650
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
37045
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
37008
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49246060
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49015120
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53816246
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1252545
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1233001
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52980643
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-572275
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
196774
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
673970
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
594826
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
500846
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
1174816
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1174816
CY2019Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5312
CY2018Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4222
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-786288
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1170594
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370389855
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1131687
CY2018Q1 hppi Proceeds From The Sale Of Preferred Stock And Common Stock Warrants Related Party Net
ProceedsFromTheSaleOfPreferredStockAndCommonStockWarrantsRelatedPartyNet
2360866
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17621
CY2019Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49315
CY2019Q1 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-835603
CY2018Q1 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-1197224
CY2019Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
99946
CY2019Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-572275
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-786288
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-1170594
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
131031
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
208243
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2467
CY2019Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-325199
CY2018Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-186957
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-977989
CY2019Q1 hppi Advances Of Royalties Related Party In Financing Activities
AdvancesOfRoyaltiesRelatedPartyInFinancingActivities
-1000000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
22011
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1229179
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1108713
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
344113
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1573292
CY2019Q1 us-gaap Stock Issued1
StockIssued1
99946
CY2019Q1 hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
49315
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
500000
CY2018Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
99945
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370446185
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370084064
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370446185
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370084064
CY2018Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
26630
CY2018Q1 hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
26630
CY2019Q1 hppi Description Of Royalty Payment
DescriptionOfRoyaltyPayment
With respect to each Advance made by Mayne Pharma prior to the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.75 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company, and with respect to each Advance made by Mayne Pharma following the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.85 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company.
CY2019Q1 hppi Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
CY2019Q1 hppi Fair Value Inputs Royalty Rate
FairValueInputsRoyaltyRate
0.70
CY2018Q4 us-gaap Deferred Revenue
DeferredRevenue
500000
CY2019Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
600000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 18pt 0px 0px 0.79in; background: none; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Estimates </div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 6pt 0px 0px 0.79in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
370446185
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Trading Symbol
TradingSymbol
HPPI
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2360866
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
166563
CY2018Q1 hppi Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
2360866
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
208243
CY2018Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
26630
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1170594
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
1538448

Files In Submission

Name View Source Status
0001193125-19-142366-index-headers.html Edgar Link pending
0001193125-19-142366-index.html Edgar Link pending
0001193125-19-142366.txt Edgar Link pending
0001193125-19-142366-xbrl.zip Edgar Link pending
d709188d10q.htm Edgar Link pending
d709188dex311.htm Edgar Link pending
d709188dex312.htm Edgar Link pending
d709188dex321.htm Edgar Link pending
d709188dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20190331.xml Edgar Link completed
hppi-20190331.xsd Edgar Link pending
hppi-20190331_cal.xml Edgar Link unprocessable
hppi-20190331_def.xml Edgar Link unprocessable
hppi-20190331_lab.xml Edgar Link unprocessable
hppi-20190331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending